Please Wait.....
Report
Human Microbiome-based Drugs and Diagnostics: Global Markets
Market Research Report I 2025-05-23 I 116 Pages I BCC Research
Description
Report Scope
The report analyzes the global market for human microbiome-based drugs and diagnostics and market trends. It includes global revenues for the base year 2024, estimated data for 2025 and the compound annual growth rates (CAGRs) for forecast period of 2025 to 2030. The market is segmented by type, application, end user and region. The microbiome-based drug segment is further segmented by route of administration: oral or rectal. Microbiome-based diagnostics are segmented based on product type into instruments, and reagents and kits. End-user segments include hospitals and clinics, pharmaceutical companies and research institutes. Applications include metabolic, gastrointestinal (GI) and infectious diseases, cancer and others. The regions covered include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA). The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) developments.
Human microbiome-based products that are intended for wellness or as dietary supplements are outside the scope of the report, as are nonstandardized fecal microbiota transplantation (FMT) procedures. Microbiome-based diagnostics include only products that claim to detect or screen for any disease or condition.
Report Includes
- 55 data tables and 51 additional tables
- Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
- Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
- Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments
- An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- An analysis of the key patent grants and recently published patents
- Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook
- Profiles of the leading companies, including Ferring Pharmaceuticals, Nestl Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc.
Executive Summary
Summary:
The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.
Human microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestl Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Biosciences.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics
Emerging Technologies
Analysis by Segment
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview and Market Definition
Different Microbiomes in Humans
Microbiome, Human Health and Disease
Technologies Aiding Microbiome Research
Culturing and Cultivation
Strategies for the Development of Microbiome Therapeutics
Additive Microbiome Therapy
Modulatory Microbiome Therapy
Analysis of Macroeconomic Factors
Geopolitical Factors
Inflation and Currency Exchange Fluctuations
Porter's Five Forces Analysis
Chapter 3 Market Dynamics
Takeaways
Market Drivers
Growing Evidence of Microbiome-disease Correlation
Microbiome-based Diagnostics for Disease Prevention and Monitoring
Market Restraints
Challenges in Clinical Trial Design
Lack of Established Regulatory Frameworks
High Costs of Microbiome Therapeutics
Market Opportunities
Direct-to-Consumer Microbiome Testing
Drugs and Diagnostics for Lung and Skin Microbiomes
Chapter 4 Regulatory Landscape
Regulatory Aspects
North America
Europe
Asia-Pacific
Chapter 5 Emerging Technologies
Takeaways
Emerging Technologies
Microbial Ecosystem Therapeutics
Metatranscriptome Sequencing
Genetically Modified Microbiome Therapeutics
Combination and Adjuvant Therapies with Microbiome-based Drugs
Novel Preclinical Models
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Type
Microbiome-based Drugs
Market Analysis by Application
Infectious Diseases
GI Disorders
Metabolic Disorders
Cancer
Other Diseases
Market Analysis by End User
Hospitals and Clinics
Research Institutions
Pharmaceutical Companies
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
South America
Middle East and Africa
Chapter 7 Competitive Intelligence
Takeaways
Company Share Analysis
Competitive Analysis
Venture Funding and Investment Landscape
Recent Developments
Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective
Introduction to ESG
ESG Risk Ratings
Concluding Remarks
Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
BIOMEBANK
ENTEROBIOTIX LTD.
ENTEROME
FERRING
GENETIC ANALYSIS
ILLUMINA INC.
MICROBIOME INSIGHTS
MICROBIOTICA
NESTLE HEALTH SCIENCE
OXFORD NANOPORE TECHNOLOGIES PLC
PACBIO
SFA THERAPEUTICS INC.
THERMO FISHER SCIENTIFIC INC.
VEDANTA BIOSCIENCES INC.
Emerging Start-ups/Market Disruptors
List of Tables
Summary Table : Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030
Table 1 : Technology for Microbiome Research
Table 2 : Diseases Associated with Microbiome Dysbiosis
Table 3 : Microbiome-based Drug Nomenclature
Table 4 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 5 : Global Market for Human Microbiome-based Drugs, by Route of Administration, Through 2030
Table 6 : Global Market for Human Microbiome-based Drugs, by Region, Through 2030
Table 7 : Global Market for Human Microbiome-based Drugs, by Rectal Route of Administration, by Region, Through 2030
Table 8 : Global Market for Human Microbiome-based Drugs, by Oral Route of Administration, by Region, Through 2030
Table 9 : Global Market for Human Microbiome-based Diagnostics, by Region, Through 2030
Table 10 : Global Market for Human Microbiome-based Diagnostics, by Product Type, Through 2030
Table 11 : Global Market for Human Microbiome-based Diagnostics Reagents and Kits, by Region, Through 2030
Table 12 : Global Market for Human Microbiome-based Diagnostic Instruments, by Region, Through 2030
Table 13 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 14 : Global Market for Human Microbiome-based Drugs and Diagnostics for Infectious Diseases, by Region, Through 2030
Table 15 : Global Market for Human Microbiome-based Drugs and Diagnostics for GI Disorders, by Region, Through 2030
Table 16 : Global Market for Human Microbiome-based Drugs and Diagnostics for Metabolic Disorders, by Region, Through 2030
Table 17 : Global Market for Human Microbiome-based Drugs and Diagnostics for Cancer, by Region, Through 2030
Table 18 : Microbiome-based Drugs in the Pipeline for Cancer Therapy
Table 19 : Global Market for Human Microbiome-based Drugs and Diagnostics for Other Diseases, by Region, Through 2030
Table 20 : Global Market for Human Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 21 : Global Market for Microbiome-based Drugs and Diagnostics for Hospitals and Clinics, by Region, Through 2030
Table 22 : Global Market for Microbiome-based Drugs and Diagnostics for Research Institutions, by Region, Through 2030
Table 23 : Global Market for Microbiome-based Drugs and Diagnostics for Pharmaceutical Firms, by Region, Through 2030
Table 24 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030
Table 25 : North American Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
Table 26 : North American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 27 : North American Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 28 : North American Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 29 : North American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 30 : North American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 31 : European Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
Table 32 : European Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 33 : European Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 34 : European Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 35 : European Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 36 : European Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 37 : Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030
Table 38 : Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 39 : Asia-Pacific Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 40 : Asia-Pacific Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 41 : Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 42 : Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 43 : South American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 44 : South American Market for Microbiome-based Drugs, by Route of Administration, Through 2030
Table 45 : South American Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 46 : South American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 47 : South American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 48 : MEA Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030
Table 49 : MEA Market for Microbiome-based Drugs, by Administration Route, Through 2030
Table 50 : MEA Market for Microbiome-based Diagnostics, by Product Type, Through 2030
Table 51 : MEA Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030
Table 52 : MEA Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030
Table 53 : Competitive Analysis of Human Microbiome-based Diagnostics Market
Table 54 : Venture Funding in the Human Microbiome-based Drugs and Diagnostics Market, 2024
Table 55 : Recent Developments in the Human Microbiome-based Drug and Diagnostics Market, 2022-2025
Table 56 : ESG Goals of Human Microbiome-based Drugs and Diagnostics Companies
Table 57 : ESG Risk Ratings for Human Microbiome-based Drugs and Diagnostics Firms, 2025
Table 58 : Report Information Sources
Table 59 : Abbreviations Used in this Report
Table 60 : BiomeBank: Company Snapshot
Table 61 : BiomeBank: Product Portfolio
Table 62 : BiomeBank: News/Key Developments, 2024
Table 63 : EnteroBiotix Ltd.: Company Snapshot
Table 64 : EnteroBiotix Ltd.: Product Portfolio
Table 65 : EnteroBiotix Ltd.: News/Key Developments, 2024
Table 66 : Enterome: Company Snapshot
Table 67 : Enterome: Product Portfolio
Table 68 : Enterome: News/Key Developments, 2022
Table 69 : Ferring: Company Snapshot
Table 70 : Ferring: Financial Performance, FY 2022 and 2023
Table 71 : Ferring: Product Portfolio
Table 72 : Ferring: News/Key Developments, 2022 and 2023
Table 73 : Genetic Analysis: Company Snapshot
Table 74 : Genetic Analysis: Financial Performance, FY 2023 and 2024
Table 75 : Genetic Analysis: Product Portfolio
Table 76 : Genetic Analysis: News/Key Developments, 2024
Table 77 : Illumina Inc.: Company Snapshot
Table 78 : Illumina Inc.: Financial Performance, FY 2023 and 2024
Table 79 : Illumina Inc.: Product Portfolio
Table 80 : Microbiome Insights: Company Snapshot
Table 81 : Microbiome Insights: Product Portfolio
Table 82 : Microbiome Insights: News/Key Developments, 2024
Table 83 : Microbiotica: Company Snapshot
Table 84 : Microbiotica: Product Portfolio
Table 85 : Microbiotica: News/Key Developments, 2023
Table 86 : Nestle Health Science: Company Snapshot
Table 87 : Nestle Health Science: Product Portfolio
Table 88 : Nestle Health Science: News/Key Developments, 2024
Table 89 : Oxford Nanopore Technologies plc: Company Snapshot
Table 90 : Oxford Nanopore Technologies plc: Financial Performance, FY 2023 and 2024
Table 91 : Oxford Nanopore Technologies plc.: Product Portfolio
Table 92 : PacBio: Company Snapshot
Table 93 : PacBio: Financial Performance, FY 2023 and 2024
Table 94 : PacBio: Product Portfolio
Table 95 : PacBio: News/Key Developments, 2025
Table 96 : SFA Therapeutics Inc.: Company Snapshot
Table 97 : SFA Therapeutics Inc.: Product Portfolio
Table 98 : SFA Therapeutics Inc.: News/Key Developments, 2024
Table 99 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 100 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 101 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 102 : Vedanta Biosciences Inc.: Company Snapshot
Table 103 : Vedanta Biosciences Inc.: Product Portfolio
Table 104 : Vedanta Biosciences Inc.: News/Key Developments, 2023
Table 105 : Emerging Startups
List of Figures
Summary Figure : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024
Figure 1 : Essential Functions of the Human Microbiome
Figure 2 : Porter's Five Forces Analysis of the Human Microbiome-based Drugs and Diagnostics Market
Figure 3 : Human Microbiome-based Drugs and Diagnostics Market Dynamics
Figure 4 : Diseases and Conditions Associated with Dysbiosis
Figure 5 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Type, 2024
Figure 6 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Application, 2024
Figure 7 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by End User, 2024
Figure 8 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024
Figure 9 : North American Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
Figure 10 : European Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
Figure 11 : Asia-Pacific Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024
Figure 12 : Company Shares in the Human Microbiome-based Drug Market, 2024
Figure 13 : Ferring: Revenue Share, by Business Unit, FY 2023
Figure 14 : Ferring: Revenue Share, by Country/Region, FY 2023
Figure 15 : Genetic Analysis: Revenue Share, by Business Unit, FY 2024
Figure 16 : Genetic Analysis: Revenue Share, by Country/Region, FY 2024
Figure 17 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
Figure 18 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
Figure 19 : Oxford Nanopore Technologies plc: Revenue Share, by Business Unit, FY 2024
Figure 20 : Oxford Nanopore Technologies plc: Revenue Share, by Country/Region, FY 2024
Figure 21 : PacBio: Revenue Share, by Business Unit, FY 2024
Figure 22 : PacBio: Revenue Share, by Country/Region, FY 2024
Figure 23 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
Figure 24 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security